Sage NMDA Modulator Fails In Alzheimer’s Months After Parkinson’s Disappointment

Dalzanemdor missed its primary endpoint in a Phase II Parkinson’s study, Sage announced, following April’s Phase II miss in Alzheimer’s. Phase II data in Huntington’s are still expected this year.